ImmuCell Corp ICCC
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ICCC is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $5.10
- Day Range
- $5.10–5.13
- 52-Week Range
- $4.26–6.05
- Bid/Ask
- $5.12 / $5.15
- Market Cap
- $39.53 Mil
- Volume/Avg
- 1,105 / 7,235
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 2.26
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 79
- Website
- https://www.immucell.com
Valuation
|
Metric
|
ICCC
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.58 |
Price/Sales | 2.26 |
Price/Cash Flow | — |
Price/Earnings
ICCC
Financial Strength
|
Metric
|
ICCC
|
|---|---|
Quick Ratio | 0.76 |
Current Ratio | 2.73 |
Interest Coverage | −11.34 |
Quick Ratio
ICCC
Profitability
|
Metric
|
ICCC
|
|---|---|
Return on Assets (Normalized) | −13.08% |
Return on Equity (Normalized) | −21.13% |
Return on Invested Capital (Normalized) | −12.98% |
Return on Assets
ICCC
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Yfrlphshl | Lpcks | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Ftjrztm | Lkdgn | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Vdlvxzj | Hkvdxj | $97.8 Bil | |
MRNA
| Moderna Inc | Lgwzsfntg | Xpgc | $38.8 Bil | |
ARGX
| argenx SE ADR | Ljnyygbgs | Dyf | $22.0 Bil | |
BNTX
| BioNTech SE ADR | Hshhylhv | Wdyw | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Pbhblwq | Nsdspw | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Bzszdqhjd | Nyjqc | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Dmjqvyjzzn | Yttnbn | $12.5 Bil | |
INCY
| Incyte Corp | Dlmjxymd | Vwnwz | $11.5 Bil |